Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][14] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, or $0.00 per share, compared to a net loss of $3.2 million, or $0.02 per share in Q4 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, with a focus on high-margin products expected to drive future growth [7][8] - Sales and marketing expenses for Q4 2025 were $10.9 million, down from $11.7 million in Q4 2024, primarily due to reduced commission expenses [15] - Research and development expenses decreased to $459,000 in Q4 2025 from $522,000 in Q4 2024 [15] Market Data and Key Metrics Changes - The company anticipates continued organic growth in its core biologics business, with expectations for revenue in 2026 to be between $95 million and $99 million [12] - The loss of license revenue from Q-Code and amniotic membrane agreements is expected to impact 2026 revenue, but the company is optimistic about ramping up its advanced wound care products [28][29] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business following the sale of non-core assets, which is seen as a transformational move [5][6] - Plans to double the number of regional sales representatives and expand the national accounts team are in place to drive institutional adoption and revenue growth [9][12] - The company is committed to maintaining positive free cash flow and does not anticipate the need for additional outside capital [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational discipline and the successful execution of strategic initiatives aimed at self-sustainability and cash flow generation [8][12] - The outlook for 2026 includes expectations for sequential quarter-over-quarter growth, driven by new product offerings and an expanded commercial organization [26] Other Important Information - The gross margin for Q4 2025 was 54.9%, an increase from 50.8% in Q4 2024, attributed to a favorable sales mix [14] - The company had $17.3 million in cash equivalents and restricted cash as of December 31, 2025, compared to $6.2 million a year earlier [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, with biologics in Q1 anticipated to be down low double digits compared to Q1 2025 due to headwinds from lost amnio product [26][27] Question: Impact of loss of license revenue from Q-Codes - The Q-Code revenue will completely go away, but management anticipates ramping up sales of their own branded products in advanced wound care as the year progresses [28][29] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected throughout the year, with a projected decline approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products like OsteoVive Plus and CollagenX, with approximately 20-22% of growth expected from OEM channels [36][40] Question: Strategic thoughts on hardware business and gross margin in 2026 - Management is evaluating the hardware business as a potential strategic distraction but sees current offerings as strong. Gross margin for 2026 is expected to be in the low 60s percentage [46][48]

Core Insights - The company achieved a top-line growth of 22% for the year, primarily driven by the Nissens acquisition, while organic growth remained stable at approximately 4% [1] Group 1: Performance Drivers - Vehicle Control performance benefited from the non-discretionary nature of products and professional repair shop demand, which typically outperforms in uncertain economic climates [1] - Temperature Control growth was fueled by an elongating air conditioning season and the increased adoption of pre-packed A/C kits that simplify complex repairs [1] Group 2: Market Position and Strategy - The Nissens segment outperformed the broader European market softening through market share gains in Eastern and Southern Europe and a focus on non-discretionary categories [1] - Engineered Solutions experienced a mid-2025 reversal of sluggish demand, returning to sequential improvement as market conditions for new equipment stabilized [1] Group 3: Management Insights - Management attributes resilience to a diverse global footprint and the ability to pass through tariff costs to price-inelastic end consumers [1]

Core Viewpoint - The company's Q4 performance exceeded expectations, driven by a gradual recovery in the industrial and ADAS sectors, along with aggressive cost-cutting measures [1] Group 1: Financial Performance - Industrial sales, the largest segment at 27% of revenue, experienced high single-digit growth due to market recovery and gains in market share from traditional customers [1] - The company achieved an 8% reduction in full-year operating expenses through a simplified operating model and leaner cost profile implemented in late 2025 [1] Group 2: Strategic Focus - The primary strategic focus for 2026 is shifting towards top-line growth and market share expansion across all global regions [1] - A 'customer-centric' reorganization is being implemented to enhance strategic positioning, aimed at accelerating new product introductions and securing design wins in adjacent markets [1] Group 3: Capital Allocation - The company prioritized a disciplined capital allocation strategy, allocating $52 million for share repurchases while maintaining a strong net cash position of $197 million [1]